T cells engineered to express a tumor-specific T-cell receptor, mediating peptide–HLA–restricted recognition and cytotoxicity.
T cells are genetically engineered to express a tumor-specific T-cell receptor that recognizes peptide antigens presented by specific HLA molecules; upon TCR engagement, the cells activate and mediate MHC/HLA-restricted tumor cell killing via perforin/granzyme release and cytokine-driven cytotoxicity.
YES
DIRECT
Engineered TCR-T cells recognize the tumor peptide–HLA class I complex and directly kill target cells via cytotoxic synapse formation with perforin/granzyme-mediated apoptosis (and Fas–FasL), with cytokine-supported cytotoxicity.
T cells engineered to express a tumor-specific T-cell receptor, mediating peptide–HLA–restricted recognition and cytotoxicity.
T cells are genetically engineered to express a tumor-specific T-cell receptor that recognizes peptide antigens presented by specific HLA molecules; upon TCR engagement, the cells activate and mediate MHC/HLA-restricted tumor cell killing via perforin/granzyme release and cytokine-driven cytotoxicity.
NO
INDIRECT
TCR-T cells kill only when their TCR recognizes a specific tumor peptide presented by the correct HLA molecule, triggering perforin/granzyme-mediated cytolysis. Expression of HLA class I heavy chain alone (without the cognate peptide) does not trigger killing.
Ex vivo expanded TILs infused to restore antitumor immunity and kill tumor cells via TCR recognition and cytotoxic effector functions.
Autologous TILs are isolated from the tumor, expanded ex vivo, and reinfused as a polyclonal T‑cell product that recognizes tumor antigens via native, HLA‑restricted TCRs and eliminates tumor cells through cytotoxic effector functions (perforin/granzyme) and cytokine release, restoring antitumor immunity without genetic engineering.
YES
DIRECT
Infused TILs recognize neoantigen peptide–HLA class I complexes via native TCRs and directly kill target cells through perforin/granzyme-mediated cytotoxicity (and death-receptor pathways).
Ex vivo expanded TILs infused to restore antitumor immunity and kill tumor cells via TCR recognition and cytotoxic effector functions.
Autologous TILs are isolated from the tumor, expanded ex vivo, and reinfused as a polyclonal T‑cell product that recognizes tumor antigens via native, HLA‑restricted TCRs and eliminates tumor cells through cytotoxic effector functions (perforin/granzyme) and cytokine release, restoring antitumor immunity without genetic engineering.
YES
DIRECT
Infused TILs recognize tumor-associated peptide-HLA class I complexes via their native TCRs and directly kill the target cell through cytolytic granule release (perforin/granzyme) and Fas-FasL–mediated apoptosis.
Ex vivo expanded TILs infused to restore antitumor immunity and kill tumor cells via TCR recognition and cytotoxic effector functions.
Autologous TILs are isolated from the tumor, expanded ex vivo, and reinfused as a polyclonal T‑cell product that recognizes tumor antigens via native, HLA‑restricted TCRs and eliminates tumor cells through cytotoxic effector functions (perforin/granzyme) and cytokine release, restoring antitumor immunity without genetic engineering.
YES
DIRECT
TILs recognize tumor-derived peptide–HLA class II via native TCRs and kill the presenting cell through cytotoxic effector functions (perforin/granzyme and/or Fas–FasL).